@PsychedVantage Psychedelic Vantage
Psychedelic Vantage posts on X about $atai, $ghrs, $cmps, $cybn the most. They currently have [-----] followers and [---] posts still getting attention that total [---] engagements in the last [--] hours.
Engagements: [---] #
- [--] Week [-----] -43%
- [--] Month [------] -87%
- [--] Months [-------] +175%
- [--] Year [-------] +482%
Mentions: [--] #
- [--] Week [--] -16%
- [--] Month [--] -13%
- [--] Months [---] +66%
- [--] Year [---] +211%
Followers: [-----] #
- [--] Week [-----] +0.34%
- [--] Month [-----] +0.91%
- [--] Months [-----] +26%
- [--] Year [-----] +74%
CreatorRank: [---------] #
Social Influence
Social category influence stocks 71.84% finance 19.42% exchanges 6.8% travel destinations 1.94% vc firms 1.94% financial services 0.97%
Social topic influence $atai #3, $ghrs #2, $cmps #6, $cybn #2, $mnmd #2, in the 9.71%, $help #9, business 5.83%, nasdaq #1285, link 4.85%
Top accounts mentioned or mentioned by @c2412345 @4andahalffarm @atailife @cangermayer @ataibeckley @flobrand @larswilde @psychedalpha @investingincan1 @andre_agtc @behaviorfin @elmonogran42994 @andreagtc @compasspathway @ghresearchplcs @seckennedy @matthewherper @cdcgov @potus @nihdirectorjay
Top assets mentioned Atai Life Sciences B.V. (ATAI) GH Research PLC (GHRS) COMPASS Pathways plc (CMPS) Alto Neuroscience, Inc. (ANRO) Neumora Therapeutics, Inc. (NMRA) AbbVie Inc (ABBV)
Top Social Posts
Top posts by engagements in the last [--] hours
"Psychedelics will also get a dedicated session: a fireside chat with German billionaire investor @C_Angermayer the founder and chair of psychedelics company @ataibeckley. $ATAI https://www.politico.com/news/2025/11/11/jd-vance-rfk-jr-to-attend-maha-summit-00646397 https://www.politico.com/news/2025/11/11/jd-vance-rfk-jr-to-attend-maha-summit-00646397"
X Link 2025-11-11T20:10Z [----] followers, [----] engagements
"$ATAI Corporate Presentation November [----] Updates: EMP-01: Oral R-enantiomer of 34-methylenedioxy-methamphetamine (R-MDMA) for social anxiety disorder (SAD) Completed patient enrollment in the exploratory randomized double-blind placebo-controlled Phase 2a study of EMP-01 to assess the safety tolerability and efficacy in approximately [--] adults with SAD. Anticipate topline results from the exploratory Phase 2a study in the first quarter of [----]. https://ir.ataibeckley.com/static-files/93ac20a9-2c59-4ce6-b69d-3add22e34fc3"
X Link 2025-11-12T12:52Z [----] followers, [----] engagements
"Psychedelic Biotech in 2025: What's Next @flobrand and @LarsWilde $ATAI $CMPS $MNMD $CYBN $GHRS https://www.youtube.com/watchv=InxiAa_etho https://www.youtube.com/watchv=InxiAa_etho"
X Link 2025-12-09T17:01Z [----] followers, 10.8K engagements
"In the case you are new to this page here is our interview from [--] months ago with the CEO of GH Research Dr. Villy Valcheva $GHRS Link: https://youtu.be/2L4JGsRx_cYsi=sk5t-P3IAk7GOWAj GH Research to Announce IND Status for GH001 $GHRS https://t.co/7XSR33USjJ https://youtu.be/2L4JGsRx_cYsi=sk5t-P3IAk7GOWAj GH Research to Announce IND Status for GH001 $GHRS https://t.co/7XSR33USjJ"
X Link 2026-01-03T16:27Z [----] followers, [----] engagements
"Psychedelic company announces a financing Deep Track Capital: Say less $CMPS $MNMD $CYBN $ATAI $GHRS"
X Link 2026-01-13T13:03Z [----] followers, [----] engagements
"@4andahalfFarm $HELP is later stage than $ATAI. I was specifically criticizing past IR execution and capital allocation toward promotion. In my view that strategy hurt credibility rather than helped it"
X Link 2026-01-22T17:56Z [----] followers, [---] engagements
"Long post 🚨 $CMPS $MNMD $CYBN $ATAI $GHRS Yes this is a small dataset but we are consistently seeing better outcomes across studies evaluating psychedelics as adjunctive treatments. Whether this reflects a true synergistic effect or simply that patients are in a better psychological or physiological state when they are not required to withdraw from background medications they have been taking for years is not clear yet. It could be both. Janssen originally evaluated Spravato as an adjunctive therapy in patients who were starting a new oral antidepressant. In a monotherapy study they"
X Link 2025-12-06T04:50Z [----] followers, [----] engagements
"Compass Pathways to Host Webinar on Commercial Preparations for Treatment-Resistant Depression (TRD) and Clinical Trial Plans for Post-Traumatic Stress Disorder (PTSD) on January [--] [----] 10:00am ET $CMPS https://ir.compasspathways.com/News--Events-/news/news-details/2025/Compass-Pathways-to-Host-Webinar-on-Commercial-Preparations-for-Treatment-Resistant-Depression-TRD-and-Clinical-Trial-Plans-for-Post-Traumatic-Stress-Disorder-PTSD-on-January-7-2026-1000am-ET/default.aspx"
X Link 2025-12-09T12:02Z [----] followers, [----] engagements
"One lesson Ive learned as a retail investor in the neuropsych space: I shouldnt assume the market or competition is always aware of all publicly available information. $ANRO looked too good to be true when it was an $80M market cap company so I sized it small. That position is now much larger. Plenty of risk remains but Im holding. Another name I think is currently being overlooked is $CYBN. CYB004 (short-duration psychedelic) has composition-of-matter IP and data expected in Q1 [----] 🤞 This is not investment advice and reflects my personal opinion."
X Link 2025-12-15T17:14Z [----] followers, [----] engagements
"Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq $CYBN https://ir.cybin.com/investors/news/news-details/2025/Cybin-to-Transfer-U-S--Stock-Exchange-Listing-to-Nasdaq/default.aspx https://ir.cybin.com/investors/news/news-details/2025/Cybin-to-Transfer-U-S--Stock-Exchange-Listing-to-Nasdaq/default.aspx"
X Link 2025-12-18T13:51Z [----] followers, [----] engagements
"$CYBN $HELP Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq $CYBN https://t.co/nhqzqqkNap Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq $CYBN https://t.co/nhqzqqkNap"
X Link 2025-12-18T19:56Z [----] followers, [----] engagements
"Nice day for $CYBN on strong volume approaching key warrant strike levels. Looking forward to Q1 data in GAD (with patients on background medication and co-morbid depression allowed in study) with CYB004 (deuterated NN-DMT delivered via intramuscular injection). CYB004 is protected by a U.S. composition of matter patent expected to provide coverage until at least [----]. https://twitter.com/i/web/status/2003566857480016165 https://twitter.com/i/web/status/2003566857480016165"
X Link 2025-12-23T20:42Z [----] followers, [----] engagements
"GH Research to Announce IND Status for GH001 $GHRS https://investor.ghres.com/news-releases/news-release-details/gh-research-announce-ind-status-gh001 https://investor.ghres.com/news-releases/news-release-details/gh-research-announce-ind-status-gh001"
X Link 2026-01-02T21:02Z [----] followers, [----] engagements
"I like $CMPS a lot but do not currently hold the stock. I personally like to make concentrated bets in the space and I also try not to get married to a stock. I think you can make a great bull thesis for all big five publicly traded companies right now. $CMPS has an exceptional team and I am confident they will build a successful company. I happen to be more optimistic about the compounds $ATAI and $CYBN are working with (and no not just because BPL-003 VLS-01 and CYB004 are shorter acting though this is a bonus) and with $CYBN especially I view the stock as being incredibly undervalued as of"
X Link 2026-01-04T21:31Z [----] followers, [---] engagements
"Compass Pathways Establishes Strategic Collaboration with Radial to Innovate Patient Experience and Inform Potential Delivery Model of COMP360 $CMPS https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Establishes-Strategic-Collaboration-with-Radial-to-Innovate-Patient-Experience-and-Inform-Potential-Delivery-Model-of-COMP360/default.aspx https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Establishes-Strategic-Collaboration-with-Radial-to-Innovate-Patient-Experience-and-Inform-Potential-Delivery-Model-of-COMP360/default.aspx"
X Link 2026-01-06T12:01Z [----] followers, [---] engagements
"Excited to tune into this one There should be a recording in the news/events section of the $CMPS website if you cannot listen in live. Cheers 🍄 January [--] 10:00 am ET Link to webcast: https://t.co/sMO2qd5RfD $CMPS January [--] 10:00 am ET Link to webcast: https://t.co/sMO2qd5RfD $CMPS"
X Link 2026-01-07T00:26Z [----] followers, [---] engagements
"Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD $CMPS https://www.businesswire.com/news/home/20260107267454/en/Compass-Pathways-Announces-FDA-Acceptance-of-IND-Application-for-PTSD-and-Hosts-Webinar-on-PTSD-and-TRDfeedref=JjAwJuNHiystnCoBq_hl-aZB5jvwAGck0gcl1t4KPzrHre1DJVAyGv2KUgXc6KI-rCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3nxKm_sU1fDX96UCOdFPTxd02TcmFSMed6acgQOfyvwRA%3D%3D"
X Link 2026-01-07T13:06Z [----] followers, [---] engagements
"COMPASS Pathways investor presentation January [----] $CMPS https://s204.q4cdn.com/927483861/files/doc_presentation/2026/01/updated/CMPS-investor-presentation_final-for-posting-Jan-7.pdf https://s204.q4cdn.com/927483861/files/doc_presentation/2026/01/updated/CMPS-investor-presentation_final-for-posting-Jan-7.pdf"
X Link 2026-01-07T14:58Z [----] followers, [---] engagements
"$CMPS [--] week high"
X Link 2026-01-07T19:03Z [----] followers, [----] engagements
"@BehaviorFin @ElMonoGran42994 @Andre_AGTC $ATAI does have some more $CMPS shares to dump though. They have been selling around [--] mil each quarter from my memory. I believe they have around [--] million shares left"
X Link 2026-01-08T15:24Z [----] followers, [---] engagements
"$CMPS strategic collaboration partnership I am most interested in currently is with Journey clinical Link: The possibility of people being able to access psilocybin-assisted psychotherapy and potentially with a therapist they already have a relationship with is exciting #CMPS #JourneyClinical https://www.journeyclinical.com https://www.journeyclinical.com Compass Pathways to Host Webinar on Commercial Preparations for Treatment-Resistant Depression (TRD) and Clinical Trial Plans for Post-Traumatic Stress Disorder (PTSD) on January [--] [----] 10:00am ET $CMPS https://t.co/JAV6WNHR8M"
X Link 2026-01-10T14:57Z [----] followers, [----] engagements
"Trimmed around 7% of my $ANRO position in the Roth and bought more $HELP. As always this is not investment advice. Updated neuropsychiatry drug development portfolio allocation (Individual + Roth IRA) Added to $HELP position As always this is not investment advice. I share to stay transparent and spark conversation in the community. -Jake https://t.co/rh56LzDp9S Updated neuropsychiatry drug development portfolio allocation (Individual + Roth IRA) Added to $HELP position As always this is not investment advice. I share to stay transparent and spark conversation in the community. -Jake"
X Link 2026-01-12T16:16Z [----] followers, [----] engagements
"Curious if market will appreciate data a bit more when they realize the strength of the IP here (if data is good). Small study but so was Gilgameshs phase 2a with their drug candidate. Unlike Bretisilocin HLP004 is in final IM formulation 😏. Good or good enough $CMPS data will be important for the space but perhaps wont affect $GHRS stock price too much. https://twitter.com/i/web/status/2010749571215880359 https://twitter.com/i/web/status/2010749571215880359"
X Link 2026-01-12T16:23Z [----] followers, [---] engagements
"AtaiBeckley Participates in the 64th Annual ACNP Meeting with Two Scientific Poster Presentations and Hot Topic Presentation $ATAI https://ir.ataibeckley.com/news-releases/news-release-details/ataibeckley-participates-64th-annual-acnp-meeting-two-scientific https://ir.ataibeckley.com/news-releases/news-release-details/ataibeckley-participates-64th-annual-acnp-meeting-two-scientific"
X Link 2026-01-16T12:03Z [----] followers, [---] engagements
"$ATAI Corporate Presentation January [----] https://ir.ataibeckley.com/static-files/93ac20a9-2c59-4ce6-b69d-3add22e34fc3 https://ir.ataibeckley.com/static-files/93ac20a9-2c59-4ce6-b69d-3add22e34fc3"
X Link 2026-01-16T12:07Z [----] followers, [----] engagements
"@4andahalfFarm Yes which doesn't account for any potential future studies with VLS-01 and EMP-01 beyond phase 2"
X Link 2026-01-16T19:24Z [----] followers, [---] engagements
"Jake speaks with @flobrand and @LarsWilde Co-Founders of atai Life Sciences (now @ataibeckley) and @COMPASSPathway. In this conversation we discuss their backgrounds what led them into psychedelic drug development and what inspired them to start two of the most influential companies in the space. We cover the major developments of the past year including AbbVies up to $1.2 billion acquisition of Bretisilocin what we know about the compound the type of psychedelic experience it produces and why the deal terms were so significant. Florian and Lars share their views on what this deal means for"
X Link 2025-12-09T17:10Z [----] followers, [----] engagements
"A Mebufotenin Melee: Exploring IP and Exclusivity in 5-MeO-DMT Drug Development Across GH Research and Beckley Psytech by @Psyched_Alpha is a good piece to come back to and read. $GHRS $ATAI Link: Since this piece came out there have been many updates such as: Will be interesting to see how this all plays out 🐸 https://www.portasophia.org/newsroom/press-releases/all-pending-claims-rejected-for-gh-research-ireland-ltd-u-s-patent-application-describing-5-meo-dmt-to-treat-depression https://psychedelicalpha.com/news/p%CE%B1-psychedelic-patent-analysis-a-mebufotenin-melee-dec-23-jan-24 GH"
X Link 2026-01-03T16:11Z [----] followers, [----] engagements
"Meeting the Promise of Psychedelics Panel: Expected Trends for [----] @ Sachs_NIF $CMPS $DFTX $HELP $ATAI $GHRS https://youtu.be/hGhSBPlzHLYsi=WD_AmS-FMT0P0GRc https://youtu.be/hGhSBPlzHLYsi=WD_AmS-FMT0P0GRc"
X Link 2026-02-12T21:34Z [----] followers, [----] engagements
"Psychedelic drug development stock portfolio update -Jake Just purchased shares of $GHRS ahead of phase 2b data readout in TRD (Not financial advice). I will be recording a video tonight and there is A LOT to cover including but not limited to: - GH Researchs approach to administering 5-MeO-DMT. - My personal belief that 5-MeO-DMT will show superior efficacy in TRD when compared to Psilocybin overall. - Beckley Psytech exploring bi-phasic dosing of 5-MeO-DMT. (Intranasal delivery of 4mg and 8mg approximately [--] minutes apart) and speculating as to why they are now exploring this dosing"
X Link 2024-12-30T15:23Z [----] followers, [----] engagements
"Neumora Therapeutics Depression Drug Fails In First Of Three Pivotal Phase [--] Trials $NMRA https://finance.yahoo.com/news/neumora-therapeutics-depression-drug-fails-133028449.html https://finance.yahoo.com/news/neumora-therapeutics-depression-drug-fails-133028449.html"
X Link 2025-01-02T13:54Z [----] followers, [---] engagements
"GH Research Announces Primary Endpoint Met in Two Phase 2a POC Trials with GH001 and Completion of All FDA Requests to Address IND Hold with No Findings of Respiratory Toxicity in Non-Rodents $GHRS https://www.globenewswire.com/news-release/2025/01/10/3007557/0/en/GH-Research-Announces-Primary-Endpoint-Met-in-Two-Phase-2a-POC-Trials-with-GH001-and-Completion-of-All-FDA-Requests-to-Address-IND-Hold-with-No-Findings-of-Respiratory-Toxicity-in-.html"
X Link 2025-01-10T12:08Z [----] followers, [---] engagements
"Numinus Wellness Announces Corporate Update $NUMIF https://www.investors.numinus.com/news/news-details/2025/Numinus-Wellness-Announces-Corporate-Update/default.aspx https://www.investors.numinus.com/news/news-details/2025/Numinus-Wellness-Announces-Corporate-Update/default.aspx"
X Link 2025-01-24T01:32Z [----] followers, [---] engagements
"GH Research to Provide Update on Phase 2b Trial with GH001 in TRD $GHRS https://investor.ghres.com/news-releases/news-release-details/gh-research-provide-update-phase-2b-trial-gh001-trd https://investor.ghres.com/news-releases/news-release-details/gh-research-provide-update-phase-2b-trial-gh001-trd"
X Link 2025-01-31T21:03Z [----] followers, [---] engagements
"GH Research to Provide Update on Phase 2b Trial with GH001 in TRD $GHRS Conference call live on Monday at [--] am ET: https://edge.media-server.com/mmc/p/utdsqfxk/ https://edge.media-server.com/mmc/p/utdsqfxk/"
X Link 2025-02-01T22:42Z [----] followers, [---] engagements
"GH Research Announces Proposed Public Offering $GHRS https://www.globenewswire.com/news-release/2025/02/03/3019846/0/en/GH-Research-Announces-Proposed-Public-Offering.html https://www.globenewswire.com/news-release/2025/02/03/3019846/0/en/GH-Research-Announces-Proposed-Public-Offering.html"
X Link 2025-02-03T21:12Z [----] followers, [---] engagements
"GH Research Reports Full Year [----] Financial Results and Provides Business Updates $GHRS https://investor.ghres.com/news-releases/news-release-details/gh-research-reports-full-year-2024-financial-results-and https://investor.ghres.com/news-releases/news-release-details/gh-research-reports-full-year-2024-financial-results-and"
X Link 2025-02-27T12:02Z [----] followers, [---] engagements
"In case you missed it here is our most recent interview with Dr. Villy Valcheva CEO of GH Research: Topics of this interview include: Dr. Valcheva's background as a physician and experience working in pharma/biotech. The company's thought process behind choosing mebufotenin an inhalation route of administration and an individualized dosing regimen. GH001 demonstrating consistent antidepressant efficacy with re-treatment in the company's phase 2b trial in TRD. GH Research taking a unique approach with its Phase 2b trial design compared to other psychedelic drug developers. With the recent"
X Link 2025-03-10T19:18Z [----] followers, [---] engagements
"GH Research Reports First Quarter [----] Financial Results and Provides Business Updates $GHRS https://investor.ghres.com/news-releases/news-release-details/gh-research-reports-first-quarter-2025-financial-results-and https://investor.ghres.com/news-releases/news-release-details/gh-research-reports-first-quarter-2025-financial-results-and"
X Link 2025-05-08T11:04Z [----] followers, [---] engagements
"GH Research Announces Acceptance of Pharmaceutical Pipeline Presentation and Late-Breaking Posters at the American Society of Clinical Psychopharmacology [----] Annual Meeting $GHRS https://investor.ghres.com/news-releases/news-release-details/gh-research-announces-acceptance-pharmaceutical-pipeline https://investor.ghres.com/news-releases/news-release-details/gh-research-announces-acceptance-pharmaceutical-pipeline"
X Link 2025-05-15T11:09Z [----] followers, [---] engagements
"There are ongoing clinical trials that are going to read out sometime soon and we have to take an expeditious and rapid review of that data - FDA commissioner Dr. Marty Makary $GHRS $MNMD $CMPS $ATAI $CYBN FDA commissioner says research on psychedelic treatment top priority' On Balance https://t.co/TsiU0b9SJk $GHRS $MNMD $CMPS $ATAI $CYBN FDA commissioner says research on psychedelic treatment top priority' On Balance https://t.co/TsiU0b9SJk $GHRS $MNMD $CMPS $ATAI $CYBN"
X Link 2025-05-17T14:47Z [----] followers, [----] engagements
"GH Research poster presentations: $GHRS https://investor.ghres.com/node/7926/html GH Research Announces Acceptance of Pharmaceutical Pipeline Presentation and Late-Breaking Posters at the American Society of Clinical Psychopharmacology [----] Annual Meeting $GHRS https://t.co/vCLzFWArIs https://investor.ghres.com/node/7926/html GH Research Announces Acceptance of Pharmaceutical Pipeline Presentation and Late-Breaking Posters at the American Society of Clinical Psychopharmacology [----] Annual Meeting $GHRS https://t.co/vCLzFWArIs"
X Link 2025-05-21T13:29Z [----] followers, [----] engagements
"@SecKennedy @matthewherper @CDCgov @POTUS @NIHDirector_Jay @DrMakaryFDA Long covid has entered the chat"
X Link 2025-05-27T15:13Z [----] followers, 24.4K engagements
"GH Research Submits Complete IND Hold Response to FDA Ahead of Schedule $GHRS https://investor.ghres.com/news-releases/news-release-details/gh-research-submits-complete-ind-hold-response-fda-ahead https://investor.ghres.com/news-releases/news-release-details/gh-research-submits-complete-ind-hold-response-fda-ahead"
X Link 2025-06-20T17:06Z [----] followers, [---] engagements
"Welcome back Cathie. $ATAI $ARKG https://www.investing.com/news/company-news/cathie-woods-ark-etf-adjusts-portfolio-buys-tesla-and-atai-stock-93CH-4120225 https://www.investing.com/news/company-news/cathie-woods-ark-etf-adjusts-portfolio-buys-tesla-and-atai-stock-93CH-4120225"
X Link 2025-07-02T02:06Z [----] followers, [----] engagements
"Single-dose (10 mg) psilocybin reduces symptoms in adults with obsessive-compulsive disorder: A pharmacological challenge study https://www.sciencedirect.com/science/article/pii/S0010440X25000471 https://www.sciencedirect.com/science/article/pii/S0010440X25000471"
X Link 2025-07-03T14:22Z [----] followers, [---] engagements
"GH Research stock awaits FDA response on clinical hold says Canaccord $GHRS https://www.investing.com/news/analyst-ratings/gh-research-stock-awaits-fda-response-on-clinical-hold-says-canaccord-93CH-4129814 https://www.investing.com/news/analyst-ratings/gh-research-stock-awaits-fda-response-on-clinical-hold-says-canaccord-93CH-4129814"
X Link 2025-07-11T18:05Z [----] followers, [---] engagements
"Very informative episode A big thank you to @AdvisorShares and @ElemerPiros #AlphaNooner Deep Dive into Psychedelic Biotech with Elemer Piros PhD https://t.co/Ck4JBeVMuW #AlphaNooner Deep Dive into Psychedelic Biotech with Elemer Piros PhD https://t.co/Ck4JBeVMuW"
X Link 2025-07-22T21:21Z [----] followers, [---] engagements
"GH Research Announces Global Pivotal Program Plans and Further Development Updates $GHRS https://investor.ghres.com/news-releases/news-release-details/gh-research-announces-global-pivotal-program-plans-and-further https://investor.ghres.com/news-releases/news-release-details/gh-research-announces-global-pivotal-program-plans-and-further"
X Link 2025-07-23T12:55Z [----] followers, [---] engagements
"GH Research R&D Update July [----] $GHRS Presentation: https://investor.ghres.com/static-files/68e55af4-a7da-499c-aa99-2e0656b6ab89 https://investor.ghres.com/static-files/68e55af4-a7da-499c-aa99-2e0656b6ab89"
X Link 2025-07-23T20:56Z [----] followers, [---] engagements
"GH Research Reports Second Quarter [----] Financial Results and Provides Business Updates $GHRS https://investor.ghres.com/news-releases/news-release-details/gh-research-reports-second-quarter-2025-financial-results-and https://investor.ghres.com/news-releases/news-release-details/gh-research-reports-second-quarter-2025-financial-results-and"
X Link 2025-08-07T11:06Z [----] followers, [---] engagements
"Inside the PSIL ETF (NYSE: $PSIL) Dan Ahrens @InvestinginCan1 on Psychedelic Investing https://www.youtube.com/watchv=qdWpmUXHIgE https://www.youtube.com/watchv=qdWpmUXHIgE"
X Link 2025-08-19T12:01Z [----] followers, [----] engagements
"(NYSE: $PSIL) Inside the PSIL ETF (NYSE: $PSIL) Dan Ahrens @InvestinginCan1 on Psychedelic Investing https://t.co/8dsKXb5zFw Inside the PSIL ETF (NYSE: $PSIL) Dan Ahrens @InvestinginCan1 on Psychedelic Investing https://t.co/8dsKXb5zFw"
X Link 2025-08-19T12:11Z [----] followers, [---] engagements
"From: American College of Neuropsychopharmacology Annual Meeting December 8-11 [----] Poster #M59: SPL026 (DMT fumarate) in combination with Selective Serotonin Reuptake Inhibitors (SSRIs) for patients with Major Depressive Disorder (MDD) Absolutely fascinating data here (yes small sample size). This was looking at IV NN-DMT. $CYBN CYB004 (Deuterated NN-DMT IM formulation) is expected to elicit a [--] minute experience. Peak effects in 3-5 min (Seems ideal for GAD patients not much time to sit around waiting). Compared to IV NN-DMT patients will have more time in the CYB004 experience. Most"
X Link 2025-08-29T22:20Z [----] followers, [----] engagements
"atai Life Sciences Awarded Grant from the National Institutes of Health $ATAI https://www.globenewswire.com/news-release/2025/09/18/3152334/0/en/atai-Life-Sciences-Awarded-Grant-from-the-National-Institutes-of-Health.html https://www.globenewswire.com/news-release/2025/09/18/3152334/0/en/atai-Life-Sciences-Awarded-Grant-from-the-National-Institutes-of-Health.html"
X Link 2025-09-18T13:31Z [----] followers, [----] engagements
"@C_Angermayer @atai_life Awesome news"
X Link 2025-09-18T13:38Z [----] followers, [---] engagements
"$ATAI October [----] Corporate Presentation https://ir.atai.com/static-files/93ac20a9-2c59-4ce6-b69d-3add22e34fc3 https://ir.atai.com/static-files/93ac20a9-2c59-4ce6-b69d-3add22e34fc3"
X Link 2025-10-07T15:11Z [----] followers, [----] engagements
"GH Research Announces Novel Therapies Symposium Presentation and Posters at the [----] ECNP Congress $GHRS https://investor.ghres.com/news-releases/news-release-details/gh-research-announces-novel-therapies-symposium-presentation-and https://investor.ghres.com/news-releases/news-release-details/gh-research-announces-novel-therapies-symposium-presentation-and"
X Link 2025-10-09T11:02Z [----] followers, [---] engagements
"atai Life Sciences and Beckley Psytech Announce U.S. FDA Breakthrough Therapy Designation Granted to BPL-003 Underscoring its Potential in Treatment-Resistant Depression $ATAI https://ir.atai.com/news-releases/news-release-details/atai-life-sciences-and-beckley-psytech-announce-us-fda https://ir.atai.com/news-releases/news-release-details/atai-life-sciences-and-beckley-psytech-announce-us-fda"
X Link 2025-10-16T20:12Z [----] followers, [----] engagements
"$MNMD surpasses $1 billion dollar market cap"
X Link 2025-10-17T19:42Z [----] followers, [----] engagements
"What a day what a year. Neuropsych portfolio up over 350% YTD. Euphoria kicked in today when I saw the value of the portfolio. This was sign to me that I needed to take more money off the table. I have trimmed around 20% of the portfolio this year. Holding onto $ANRO for dear life though. Trimmed tiny amounts of $ATAI today (75% of reason it takes up such a large chunk of the neuropsych portfolio is because I would still buy at todays prices and 25% is emotional attachment which is something I really need to address). Also sold a bit more $CMPS today. I think $ATAI $CMPS $ANRO and $VTGN (more"
X Link 2025-10-20T16:40Z [----] followers, [----] engagements
"Tbh not sure what to make of it. I personally (again personally) wrote off that program 1-2 years ago. Agreed cardiac issues make it very difficult to develop this psychedelic. It isnt mentioned anywhere in atai investor presentation or website. More than happy with BPL-003 VLS-01 EMP-01 and discovery program moving forward. -Jake https://twitter.com/i/web/status/1980885107863908808 https://twitter.com/i/web/status/1980885107863908808"
X Link 2025-10-22T06:33Z [----] followers, [--] engagements
"Cybin to Participate at the [----] Milken Institute Future of Health Summit $CYBN https://ir.cybin.com/investors/news/news-details/2025/Cybin-to-Participate-at-the-2025-Milken-Institute-Future-of-Health-Summit/default.aspx https://ir.cybin.com/investors/news/news-details/2025/Cybin-to-Participate-at-the-2025-Milken-Institute-Future-of-Health-Summit/default.aspx"
X Link 2025-11-03T12:32Z [----] followers, [---] engagements
"GH Research Reports Third Quarter [----] Financial Results and Provides Business Updates $GHRS https://investor.ghres.com/news-releases/news-release-details/gh-research-reports-third-quarter-2025-financial-results-and https://investor.ghres.com/news-releases/news-release-details/gh-research-reports-third-quarter-2025-financial-results-and"
X Link 2025-11-06T13:15Z [----] followers, [---] engagements
"Corporate Presentation GH Research PLC (NASDAQ: $GHRS) November [----] https://investor.ghres.com/static-files/b2dd9ece-7c4f-4f54-ba96-71ed0a772ee1 https://investor.ghres.com/static-files/b2dd9ece-7c4f-4f54-ba96-71ed0a772ee1"
X Link 2025-11-06T13:28Z [----] followers, [---] engagements
"AtaiBeckley Announces Positive Topline Data from the Phase 2b Open-Label Extension Study of BPL-003 Supporting Safety and Efficacy of a Second Dose in Patients with Treatment-Resistant Depression $ATAI https://ir.ataibeckley.com/news-releases/news-release-details/ataibeckley-announces-positive-topline-data-phase-2b-open-label https://ir.ataibeckley.com/news-releases/news-release-details/ataibeckley-announces-positive-topline-data-phase-2b-open-label"
X Link 2025-11-10T12:03Z [----] followers, [----] engagements
"$ATAI AtaiBeckley Announces Positive Topline Data from the Phase 2b Open-Label Extension Study of BPL-003 Supporting Safety and Efficacy of a Second Dose in Patients with Treatment-Resistant Depression $ATAI https://t.co/ofdtbKlFAI AtaiBeckley Announces Positive Topline Data from the Phase 2b Open-Label Extension Study of BPL-003 Supporting Safety and Efficacy of a Second Dose in Patients with Treatment-Resistant Depression $ATAI https://t.co/ofdtbKlFAI"
X Link 2025-11-10T12:06Z [----] followers, [----] engagements
"Im not as optimistic as others about psilocybins potential to treat PTSD/complex PTSD. Im far more optimistic about the benefitrisk profile of MDMA/methylone for PTSD. Genuinely open to being convinced otherwise: what am I missing"
X Link 2025-11-11T00:39Z [----] followers, [----] engagements
"Compass Pathways at Stifel [----] Healthcare Conference $CMPS https://event.summitcast.com/view/cwkmPXkC4dosg6MoG95rxb/guest_booksession_id=BmFDXzrfmqipqHDi5XeUXn https://event.summitcast.com/view/cwkmPXkC4dosg6MoG95rxb/guest_booksession_id=BmFDXzrfmqipqHDi5XeUXn"
X Link 2025-11-12T00:20Z [----] followers, [---] engagements
"Cybin Reports Second Quarter Fiscal Year [----] Financial Results and Recent Business Highlights $CYBN https://ir.cybin.com/investors/news/news-details/2025/Cybin-Reports-Second-Quarter-Fiscal-Year-2026-Financial-Results-and-Recent-Business-Highlights/default.aspx https://ir.cybin.com/investors/news/news-details/2025/Cybin-Reports-Second-Quarter-Fiscal-Year-2026-Financial-Results-and-Recent-Business-Highlights/default.aspx"
X Link 2025-11-13T12:22Z [----] followers, [----] engagements
"AtaiBeckley to Participate in the Jefferies Global Healthcare Conference in London $ATAI https://ir.ataibeckley.com/news-releases/news-release-details/ataibeckley-participate-jefferies-global-healthcare-conference https://ir.ataibeckley.com/news-releases/news-release-details/ataibeckley-participate-jefferies-global-healthcare-conference"
X Link 2025-11-13T15:04Z [----] followers, [----] engagements
"@seedy19tron @seedytx19 Woodline Partners Venrock Healthcare Capital Partners Acorn Bioventures Rosalind Advisors Lynx1 Capital Management Foresite Capital HBM Partners"
X Link 2025-11-15T04:08Z [----] followers, [---] engagements
"Am I imagining this or has no one publicly complained about AbbVie acquiring Bretisilocin It feels like this acquisition challenges the whole pharma wants to keep people sick narrative. Curious what others think. $CMPS $MNMD $CYBN $ATAI $GHRS"
X Link 2025-11-15T20:33Z [----] followers, [----] engagements
"Compass Pathways to Participate in Two Investor Conferences in December $CMPS https://ir.compasspathways.com/News--Events-/news/news-details/2025/Compass-Pathways-to-Participate-in-Two-Investor-Conferences-in-December/default.aspx https://ir.compasspathways.com/News--Events-/news/news-details/2025/Compass-Pathways-to-Participate-in-Two-Investor-Conferences-in-December/default.aspx"
X Link 2025-11-20T11:56Z [----] followers, [---] engagements
"Jefferies Global Healthcare Conference in London $CYBN https://wsw.com/webcast/jeff332/cybn/1843684mobile=True https://wsw.com/webcast/jeff332/cybn/1843684mobile=True"
X Link 2025-11-21T02:04Z [----] followers, [----] engagements
"$CMPS $MNMD $CYBN Cantor's (more comprehensive) 1H26 catalyst watchlist $XBI $BBC https://t.co/PNsLPopjBB Cantor's (more comprehensive) 1H26 catalyst watchlist $XBI $BBC https://t.co/PNsLPopjBB"
X Link 2025-12-03T04:40Z [----] followers, [----] engagements
"2025 has been quite the year for the psychedelic drug development sector: $CMPS $MNMD $CYBN $ATAI $GHRS We have seen positive mid-late stage data coming from multiple companies across a variety of compounds targeting multiple indications. Nearly $600 million has been raised in follow-on offerings in the past several months and of course big pharma has acquired a compound in the space (and may I add one that doesn't skip the trip) So what do we have to look forward to in [----] This post will focus on clinical trial readouts: $CMPS to disclose 9-week data (Part A) from COMP006 together with"
X Link 2025-12-06T19:28Z [----] followers, [----] engagements
"Big [--] publicly trade companies are $CMPS $MNMD $CYBN $ATAI and $GHRS. You can make an argument that $DRUG is a psychedelic stock with their earlier stage programs. You also have Solvonis Therapeutics Tryptamine Therapeutics (I think they changed their name again to something else) BetterLife Pharma Clearmind Medicine and Enveric Biosciences. Outside of $CMPS $MNMD $CYBN $ATAI $GHRS and $DRUG the rest are nano caps. I am personally most bullish on $ATAI and $CYBN as I hold shares in both. But if you asked me which companies I am most bullish on in short term medium term and longterm I would"
X Link 2025-12-07T00:44Z [----] followers, [---] engagements
"@Austinmulder95 I am also in $ATAI $ANRO and $CYBN. I am excited about them as well. Hopefully good Q1 data for all [--] companies on [----] 🤞"
X Link 2025-12-15T22:59Z [----] followers, [---] engagements
"With Neuphoria Therapeutics $NEUP and now Vistagen Therapeutics $VTGN reporting unfortunate Phase [--] failures in social anxiety disorder (SAD) a common and often debilitating condition that has become more prevalent since COVID the market remains wide open for a truly effective new treatment. Im hopeful that EMP-01 $ATAI will show promising efficacy data in Q1 measured by change in LSAS total score from baseline to Day [--] with safety and tolerability as the primary endpoint over the same period. Notably there have been no new FDA-approved treatments specifically for SAD in nearly two decades"
X Link 2025-12-17T14:06Z [----] followers, [----] engagements
"@BigDogBack Q1"
X Link 2025-12-29T22:06Z [----] followers, [---] engagements
"Cybin Initiates At-The-Market Equity Program of up to US$100 Million $CYBN https://ir.cybin.com/investors/news/news-details/2025/Cybin-Initiates-At-The-Market-Equity-Program-of-up-to-US100-Million/default.aspx https://ir.cybin.com/investors/news/news-details/2025/Cybin-Initiates-At-The-Market-Equity-Program-of-up-to-US100-Million/default.aspx"
X Link 2025-12-30T20:35Z [----] followers, [----] engagements
"January [--] 10:00 am ET Link to webcast: $CMPS https://lifescievents.com/event/q0v8tp3/ Compass Pathways to Host Webinar on Commercial Preparations for Treatment-Resistant Depression (TRD) and Clinical Trial Plans for Post-Traumatic Stress Disorder (PTSD) on January [--] [----] 10:00am ET $CMPS https://t.co/JAV6WNHR8M https://lifescievents.com/event/q0v8tp3/ Compass Pathways to Host Webinar on Commercial Preparations for Treatment-Resistant Depression (TRD) and Clinical Trial Plans for Post-Traumatic Stress Disorder (PTSD) on January [--] [----] 10:00am ET $CMPS https://t.co/JAV6WNHR8M"
X Link 2026-01-03T16:13Z [----] followers, [----] engagements
"Expecting a busy next week for headlines in the psychedelic drug development space Wouldnt be surprised to see news/updates coming from all big [--] publicly traded companies $CMPS $MNMD $HELP $ATAI $GHRS"
X Link 2026-01-03T16:40Z [----] followers, [----] engagements
"One of the more complex stories to follow in 2026: $GHRS and $ATAI. Another: $CMPS Usona Institute (non-profit Phase [--] psilocybin) and Terran Biosciences new salt/polymorph strategy. The least complex story I see right now: CYB004 at Helus Pharma (formerly Cybin). I currently hold shares in $ATAI and $CYBN -Jake A Mebufotenin Melee: Exploring IP and Exclusivity in 5-MeO-DMT Drug Development Across GH Research and Beckley Psytech by @Psyched_Alpha is a good piece to come back to and read. $GHRS $ATAI Link: https://t.co/1RRn2tYKcw Since this piece came out there have been many updates A"
X Link 2026-01-03T17:05Z [----] followers, [----] engagements
"New website Link: $HELP https://www.helus.com Cybin rebranding to Helus Pharma ( $HELP ) begins ahead of its transition from NYSE American to Nasdaq effective tomorrow Curious to see if a new CEO is announced https://t.co/gZdwsAqyiy https://www.helus.com Cybin rebranding to Helus Pharma ( $HELP ) begins ahead of its transition from NYSE American to Nasdaq effective tomorrow Curious to see if a new CEO is announced https://t.co/gZdwsAqyiy"
X Link 2026-01-05T05:25Z [----] followers, [----] engagements
"Not exactly my personal takeaway from an investor lens. $GHRS still needs to complete phase [--] PK trial with proprietary device and seek FDA alignment on global phase [--] program. $ATAI has given guidance on phase [--] initiation in Q2 [----]. Keep in mind both companies are working with the same molecule. 🐸 https://twitter.com/i/web/status/2008152495139303731 https://twitter.com/i/web/status/2008152495139303731"
X Link 2026-01-05T12:23Z [----] followers, [---] engagements
"$GHRS trading up 35%+ in pre-market trading 📈 GH Research Announces FDA Lifts Clinical Hold on GH001 Clearing Path for Global Phase [--] Initiation in [----] $GHRS https://t.co/nSp0a6Le0G GH Research Announces FDA Lifts Clinical Hold on GH001 Clearing Path for Global Phase [--] Initiation in [----] $GHRS https://t.co/nSp0a6Le0G"
X Link 2026-01-05T12:38Z [----] followers, [---] engagements
"I really do like $MNMD right now. If I was more comfortable with a long-term bull thesis for them I would buy in a heartbeat. With $ATAI and $CYBN I like them in the short medium and long term. I truly believe $CYBN can eventually become a buyout target and will probably trim shares along the way if those stocks perform the way I think they will. Once you have a drug that may require more than [--] hours in the clinic I do not know if that can scale. $MNMD is now stating that they expect an 8-hour clinic visit on average though. They have an awesome team and plenty of cash and maybe I am missing"
X Link 2026-01-05T21:31Z [----] followers, [---] engagements
"Yeah definitely not an expert on the IP landscape here but I assume the ODT formulation may offer some degree of protection. No reason I have to believe it is any weaker than $CMPS. Another thing I like about LSD with $MNMD is that I personally believe it will be overall the most psychologically well-tolerated of the psychedelics in development not counting entactogens like MDMA or methylone. In terms of IP based on the folks I have spoken with CYB004 seems to be quite rock solid. I am sure CYB003 IP is also solid but not sure that will matter if generic psilocybin hits the market earlier"
X Link 2026-01-05T21:51Z [----] followers, [---] engagements
"Ill just add one last thing here: I will be heartbroken if for whatever reason data with CYB004 (now HLP004 😃) isnt good in GAD. I am obviously very big on $ATAI: Deep pipeline BPL-003 (5-MeO-DMT intranasal formulation) VLS-01 (buccal film DMT) EMP-01 (R-MDMA) and strong discovery pipeline of NCEs (recent grant from NIDA). Business savy team and IMO a company where you dont question managements desire to do what is best for shareholders. https://ir.ataibeckley.com/static-files/93ac20a9-2c59-4ce6-b69d-3add22e34fc3 https://twitter.com/i/web/status/2008300633628012849"
X Link 2026-01-05T22:12Z [----] followers, [---] engagements
"Helus Pharma Corporate Presentation January [----] $HELP https://s28.q4cdn.com/259445127/files/doc_presentations/2026/01/Helus-Corporate-Deck-January-2026.pdf https://s28.q4cdn.com/259445127/files/doc_presentations/2026/01/Helus-Corporate-Deck-January-2026.pdf"
X Link 2026-01-06T18:55Z [----] followers, [---] engagements
"$HELP [---] mil market cap"
X Link 2026-01-07T18:58Z [----] followers, [----] engagements
"Yeah that was a notable move and hard to know the full context from the outside. That said OrbiMed Venrock and Deep Track were willing to step in on the recent financing which suggests the CEO change itself wasnt a deal-breaker for those investors. Of course they were also able to invest on very favorable terms. https://twitter.com/i/web/status/2008989062523146556 https://twitter.com/i/web/status/2008989062523146556"
X Link 2026-01-07T19:48Z [----] followers, [---] engagements
"AtaiBeckley Provides Update and Outlook for [----] Ahead of J.P. Morgan Healthcare Conference $ATAI https://ir.ataibeckley.com/news-releases/news-release-details/ataibeckley-provides-update-and-outlook-2026-ahead-jp-morgan https://ir.ataibeckley.com/news-releases/news-release-details/ataibeckley-provides-update-and-outlook-2026-ahead-jp-morgan"
X Link 2026-01-08T12:12Z [----] followers, [----] engagements
"What mid-dose will $ATAI choose for the BPL-003 Phase [--] program to address the issue of functional unblinding The doseresponse relationship with 5-MeO-DMT appears less clear than with psilocybin. [--] mg is the therapeutic dose they are moving forward with. [--] mg [---] mg Other [--] mg [---] mg Other"
X Link 2026-01-08T14:09Z [----] followers, [---] engagements
"Ill share what I wrote the other day: I really do like $MNMD right now. If I was more comfortable with a long-term bull thesis for them I would buy in a heartbeat. With $ATAI and $CYBN I like them in the short medium and long term. I truly believe $CYBN can eventually become a buyout target and will probably trim shares along the way if those stocks perform the way I think they will. Once you have a drug that may require more than [--] hours in the clinic I do not know if that can scale. $MNMD is now stating that they expect an 8-hour clinic visit on average though. They have an awesome team and"
X Link 2026-01-12T20:36Z [----] followers, [---] engagements
"Definium Therapeutics Appoints Roger Adsett to Board of Directors $DFTX https://ir.definiumtx.com/news-events/press-releases/detail/211/definium-therapeutics-appoints-roger-adsett-to-board-of-directors https://ir.definiumtx.com/news-events/press-releases/detail/211/definium-therapeutics-appoints-roger-adsett-to-board-of-directors"
X Link 2026-01-29T12:01Z [----] followers, [---] engagements
"@C_Angermayer @atai_life Congratulations @C_Angermayer and to the entire team at @atai_life and @BeckleyPsytech"
X Link 2025-10-17T12:42Z [----] followers, [---] engagements
"@ikkjrpp @atai_life I certainly think that in a medical setting with trained mental health professionals involved psychedelics have a lot of potential (key word here) to safely and effectively treat anxiety disorders. -Jake"
X Link 2025-10-22T06:37Z [----] followers, [--] engagements
"Prediction for BPL-003 OLE data (I reserve the right to be wrong)👇 Keep in mind that according to footnotes in $ATAI investor presentation: Patients entering the open-label extension are randomized to receive either a single 12mg dose or a biphasic 4mg and 8mg dose approximately [--] minutes apart. Eligibility for the OLE study required completion of the Core Study and regulatory & ethical approval of the OLE protocol at the participants site. [---] out of [---] total completers were at sites with OLE protocol approval. [---] out of [---] eligible completers entered OLE screening and [---] received a"
X Link 2025-10-23T03:28Z [----] followers, [----] engagements
"@4andahalfFarm @atai_life $CMPS invested 500k in seed round/8% stake. With further financing rounds the impact of $CMPS delix investment for $ATAI is most likely insignificant. $ATAI is also continuously selling off stake in $CMPS to fund their own programs. -Jake"
X Link 2025-10-31T00:42Z [----] followers, [--] engagements
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing